Pulmonary Hypertension in the Collagen Vascular Diseases

Lynn T. Tanoue

doi:10.1055/s-2003-41089

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2003; 24(3): 287-296
DOI: 10.1055/s-2003-41089

Pulmonary Hypertension in the Collagen Vascular Diseases

Lynn T. Tanoue

Yale University School of Medicine, Section of Pulmonary and Critical Care Medicine, New Haven, Connecticut

Abstract

ABSTRACT

Pulmonary hypertension is increasingly recognized as a complication of the collagen vascular diseases. Both isolated and secondary forms of the disease may be appreciated. Pulmonary hypertension is observed with high prevalence in scleroderma and mixed connective tissue disease. It is less commonly seen in systemic lupus erythematosus, and is a rare clinical finding in rheumatoid arthritis. The diagnosis and treatment of pulmonary hypertension associated with the collagen vascular diseases mirror diagnosis and treatment for pulmonary hypertension of any etiology. Vasodilator therapy may play a particularly important role in patients with the isolated form of disease, which is most frequently associated with scleroderma.

KEYWORDS

Pulmonary hypertension - collagen vascular disease - scleroderma - mixed connective tissue disease - systemic lupus erythematosus

Full Text

References

REFERENCES

1 Roncoroni A J, Alvarez C, Molinas F. Plexogenic arteriopathy associated with pulmonary vasculitis in systemic lupus erythematosus. Respiration . 1992; 59 52-56
2 Murin S, Wiedemann H P, Matthay R A. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med . 1998; 19 641-665
3 Kishida Y, Kanai Y, Kiramochi S. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol . 1993; 20 2161-2162
4 Colby T V. Pulmonary pathology in patients with systemic autoimmune diseases. Clin Chest Med . 1998; 19 587-612
5 Palevsky H I, Gurughagavatula I. Pulmonary hypertension in collagen vascular disease. Comp Ther . 1999; 25 133-143
6 LeRoy E C. Pulmonary hypertension: the bete noire of the diffuse connective tissue diseases. Am J Med . 1991; 90 539-540
7 LeRoy E C, Black C, Fleischmajer R. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol . 1988; 15 202-205
8 Nishimaki T, Aotsuka S, Kondo H. et al . Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol . 1999; 26 2357-2362
9 Alarcon-Segovia D, Eeleze M, Oria C V. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine . 1989; 68 353-365
10 Asherson R A, Hackett D, Gharavi A E, Harris E N, Kennedy H G, Hughes G R. Pulmonary hypertensiion in systemic lupus erythematosus: a report of three cases. J Rheumatol . 1986; 13 416-420
11 Asherson R A, Cervera R. Review: antiphospholipid antibodies and the lung. J Rheumatol . 1995; 22 62-66
12 Asherson R A, Higenbottam T W, Dinh Xuan T A. Pulmonary hypertension in a lupus clinic: Experience with twenty-four patients. J Rheumatol . 1990; 17 1292
13 Gussin H AE, Ignat G P, Varga J, Teodorescu M. Anti-topoisomerase I (Anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthr Rheum . 2001; 44 376-383
14 Yoshio T, Masuyama J, Sumiya M. Antiendothelial cell antibodies and their relation to pulmonary hypertension insystemic lupus erythematosus. J Rheumatol . 1994; 21 2058-2063
15 Quismorio F P, Sharma O, Koss M. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum . 1984; 13 349-359
16 Yeo P PB, Sinniah R. Lupus cor pulmonale with electron microscope and immunofluorescent antibody studies. Ann Rheum Dis . 1975; 34 457-458
17 Sanchez O, Humberg M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax . 1999; 54 273-277
18 Sanchez O, Humbert M, Sitbon O, Nunes H, Garcia G, Simonneau G. Pulmonary hypertension associated with connective tissue diseases. Revue de Medecine Interne . 2002; 23 41-54
19 Goupille P, Fauchier L, Babuty D. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus. J Rheumatol . 1994; 21 1976-1977
20 Groen H, Bootsma H, Postma D S. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol . 1993; 20 1055-1057
21 Mahowald M L, Weir E K, Ridley D J. Pulmonary hypertension in systemic lupus ereythematosus: effect of vasodilators on pulmonary hemodynamics. J Rheumatol . 1985; 12 773-777
22 Minai O A, Dweik R A, Arroliga A C. Manifestations of scleroderma pulmonary disease. Clin Chest Med . 1998; 713-731
23 Battle R W, Davitt M A, Cooper S M. et al . Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest . 1996; 110 1515-1519
24 Bolster M B, Silver R M. Lung disease in systemic sclerosis (scleroderma). Bailliere's Clin Rheum . 1993; 7 79-97
25 Coghlan J G, Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opinion Rheumatol . 2001; 13 495-499
26 Stupi A, Steen V, Owens G. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum . 1986; 29 515-524
27 Ungerer R G, Tashkin D P, Furst D. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med . 1983; 75 65-74
28 D'Angelo W A, Fries J F, Masi A T. Pathologic observations in systemic sclerosis (scleroderma). Am J Med . 1969; 46 428-440
29 Owens G R, Follansbee W P. Cardiopulmonary manifestations of systemic sclerosis. Chest . 1987; 91 118-127
30 Yousem S A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol . 1990; 21 467-474
31 Kerin K, Yost J H. Advances in the diagnosis and management of scleroderma-related vascular complications. Comp Ther . 1998; 24 574-581
32 Steen V D, Powell D L, Medsger Jr A T. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum . 1988; 31 196-203
33 Denton C P, Cailes J B, Phillips G D, Wells A U, Black C M, Du Bois M R. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. British J Rheumatol . 1997; 36 239-243
34 Murata I, Takenaka K, Yoshinoya S. et al . Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. Chest . 1997; 111 36-43
35 Wallman L L, Penny R, Williamson D J. Pulmonary vascular aspects of systemic sclerosis. Aust NZ J Med . 1996; 26 150-153
36 Christman B W, McPherson C D, Newman J H. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med . 1992; 327 70-75
37 Vancheeswaran R, Magoulas I, Efrat G. Circulating endothelin-1 in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction?. J Rheumatol . 1994; 21 1838-1844
38 Stewart D J, Levy R D, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med . 1991; 114 464-469
39 Giaid A, Yanagisawa M, Langleben D. Expression of endothelin-1 in the lungs of patients with pulmonary hypertensiion. N Engl J Med . 1993; 328 1732-1739
40 Duchman S M, Thohan V, Kaira D. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol . 2002; 15 136-140
41 Harvey A O, Shulman L E, Tulmulty P A, Conley C L, Schoenrich E H. Systemic lupus erythematosus: review of the literature and clinical anaysis of 138 cases. Medicine . 1954; 33 291-437
42 Cervera R, Khamashta M A, Font J. et al . Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine . 1972; 72 113-124
43 Winslow T M, Ossipov M A, Fazio G P, Simonson J S, Redberg R F, Schiller N B. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J . 1995; 129 510-515
44 Simonson J S, Schiller N B, Petri M, Hellmann D B. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol . 1989; 16 918-925
45 Grigor R, Edmonds J, Lewkonia R. Systemic lupus erythematosus: a prospective analysis. Ann Rheum Dis . 1978; 37 121-128
46 Gross M, Esterly J R, Earle R H. Pulmonary alterations in systemic lupus erythematosus. Am Rev Respir Dis . 1972; 105 572-577
47 Miyata M, Suzuki K, Sakuma F. Anticardiolipin antibodies are associated wirth pulmonary hypertension in patients with mixed connective tissue disease or systemic lupus erythematosus. Int Arch Allergy Immunol . 1993; 100 351-354
48 Love P E, Santoro S A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med . 1990; 112 682-698
49 Roberts W C, High S T. The heart in systemic lupus erythematosus. Curr Probl Cardiol . 1999; 24 1-56
50 Cheng T O. Pulmonary hypertension in systemic lupus erythematosus. Mayo Clin Proc . 1999; 74 845
51 Wilson L, Tomita T, Braniecki M. Fatal pulmonary hypertension in identical twins with systemic lupus erythematosus. Hum Pathol . 1991; 22 295-297
52 Evans J. Antinuclear antibody testing in systemic autoimmune disease. Clin Chest Med . 1998; 19 613-625
53 Burdt M, Hoffman R W, Deutscher S L, Wang G S, Johnson J C, Sharp G. Long-term outcome in mixed connective tissue disease. Arthr Rheum . 1999; 42 899-909
54 Sharp G C, Irvin W S, Tan E M, Gould R G, Holman R H. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med . 1972; 52 148-159
55 Prakash U BS. Respiratory complications in mixed connective tissue disease. Clin Chest Med . 1999; 19 733-746
56 Wiener-Kronish J P, Soloinger A M, Warnock M L, Churg A, Ordonez N, Golden J A. Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis . 1981; 124 499-503
57 Sullivan W D, Hurst D J, Harmon C E. et al . A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine . 1984; 63 92-107
58 Fujii M, Adachi S, Shimizu T. Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography. J Thorac Imag . 1993; 8 54-62
59 Gabbay E, Tarala R, Will R. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med . 1997; 156 528-535
60 Remy-Jardin M, Remy J, Cortet B. Lung changes in rheumatoid arthritis: CT findings. Radiology . 1994; 193 375-382
61 Tanoue L T. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med . 1998; 19 667-685
62 Gardner D L, Duthie J R, MacLeod J, Allen W SH. Pulmonary hypertension in RA: report of a case study with intimal sclerosis of pulmonary and digital arteries. Scott Med J . 1957; 2 183-186
63 Helmers R, Galvin J, Hunninghake G W. Pulmonary manifestations associated with rheumatoid arthritis. Chest . 1991; 100 235-238
64 Dawson J K, Goodson N G, Graham D R, Lynch M P. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology . 2000; 39 1320-1325
65 Okano Y, Steen V D, Medsger T A. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemc sclerosis. Arthritis Rheum . 1992; 35 95-100
66 Rich S, Levy P S. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. Am J Med . 1984; 76 573-578
67 Fuster V, Steele P M, Edwards W D, Gersh B, McGoon M, Frye R L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation . 1984; 70 580-587
68 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med . 1992; 327 76-81
69 Barst R J, Rubin L J, Long W A. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med . 1996; 334 296-302
70 McLaughlin V V, Genthner D E, Panella M M, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med . 1998; 338 273-277
71 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation . 2002; 106 1477-1482
72 Badesch D B, Tapson V F, McGoon M D. et al . Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med . 2000; 132 425-434
73 Menon N, McAlpine L, Peacock A J, Madhok R. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthr Rheum . 1998; 41 466-469
74 Klings E S, Hill N S, Leong M H, Simms R W, Korn J H, Farber H W. Systemic sclerosis-associated pulmonary hypertension. Arthr Rheum . 1999; 42 2638-2645
75 Strange C, Bolster M, Mazur J, Taylor M, Gossage J R, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest . 2000; 118 1077-1082
76 Sitbon O, Humbert M, Sanchez O. Survival in pulmonary hypertension associated with connective tissue diseases (PH-CTD) treated with long-term epoprostenol (PGI₂): comparison with primary pulmonary hypertension (PPH). Am J Respir Crit Care Med . 1999; 159 A158
77 Barst R J. Experience and reason. Chest . 2000; 117 2-5
78 Robbins I M, Gaine S P, Schilz R, Tapson V F, Rubin L J, Loyd J E. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest . 2000; 117 14-18
79 Horn E M, Barst R J, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest . 2000; 118 1229-1230
80 Galie N, Grigioni F, Bacchi-Reggiani L. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest . 1996; 26 A48
81 Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phonomenon and systemic sclerosis. Intern Med . 1994; 33 579-582
82 Chatterjee K, De Marco T, Alpert J S. Pulmonary hypertension: hemodynamic diagnosis and management. Arch Intern Med . 2002; 162 1925-1933
83 Williamson D J, Wallman L L, Jones R. et al . Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation . 2000; 102 411-418
84 Channick R N, Simonneau G, Sitbon O. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet . 2001; 358 1119-1123
85 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med . 2002; 346 896-903
86 Lepore J J, Marco A, Pereira N L. et al . Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol . 2002; 90 677-680
87 Rosas I, Conte J, Yang S. Lung transplantation and systemic sclerosis. Ann Transplantation . 2000; 5 38-43
88 Arcasoy S M, Kotloff R M. Lung transplantation. N Engl J Med . 1999; 340 1081-1091